Neuropathy development in diabetes: The last key finding of our study noted that the prevalence of neuropathy development was higher in diabetic patients initiated on PD-1 inhibitors when compared to non-diabetic counterparts, although this difference did not reach statistical significance. This evidence concerns the gene PDCD1 and diabetes mellitus.